Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy

British Journal of Haematology

Volumn 131, Issue 3, 2005, Pages 389-394

  Iyamu, Efemwonkiekie W ^a   Cecil, Renee ^b   Parkin, Leslie ^b   Woods, Gerald ^a   Ohene Frempong, Kwaku ^b   Asakura, Toshio ^b  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Arginase; Fetal haemoglobin; Hydroxyurea; Nitric oxide; Sickle cell disease

Indexed keywords

ARGINASE; HEMOGLOBIN; HYDROXYUREA; NITRIC OXIDE SYNTHASE; ANTISICKLING AGENT; HEMOGLOBIN F;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; ENZYME ACTIVITY; ERYTHROCYTE; HUMAN; METABOLITE; PLASMA; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL; BLOOD; CHILD; DRUG EFFECT; ENZYMOLOGY; METABOLISM; SICKLE CELL ANEMIA;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; ARGINASE; CHILD; ERYTHROCYTES; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA; NITRIC OXIDE SYNTHASE;

EID: 33644810234     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05772.x     Document Type: Article

References (24)

1. Abraham D.J. Perutz M.F. (1986) Development of therapeutic agent for sickle cell disease. In: Approaches to the Therapy of Sickle Cell Anaemia (ed. by Y. Beuzard S. Charache F. Galacteros pp. 141 149. INSERM, Paris.
2. Al-khatti A. Papayannopoulou T. Knitter G. Fritsch E.F. Stamatoyannopoulos G. (1988) Co-operative enhancement of F-cell formation in baboons treated with erythropoietin and hydroxyurea. Blood, 72, 817 819.
3. Azizi E. Dror Y. Wallis K. (1970) Arginase activity in erythrocytes of healthy and ill children. Clinica Chimica Acta, 28, 391 396.
4. Beruter J. Colombo J. (1978) Purification and properties of arginase from human liver and erythrocytes. Biochemical Journal, 175, 449 454.
5. Beutler E. (1975) Red Cell Metabolism: A Manual of Biochemical Methods, 2nd edn. Grune & Stratton, New York.
6. Charache S. Terrin M.L. Moore R.D. Dover G. Barton F. Eckert S. Mcmahon R. Bonds D. (1995) Effects of hydroxyurea on the frequency of painful crises in sickle cell anemia and the investigators of the multicenter study of hydroxyurea in sickle cell anemia. New England Journal of Medicine, 332, 1317 1322.
7. Chinard F.P. (1952) Photometric estimation of proline and ornithine. Journal of Biological Chemistry, 199, 91 95.
8. Cokic V.P. Smith R.D. Belleslin-Cokic B.B. Njoroge J.M. Miller J.L. Gladwin M.T. Schechter A.N. (2003) Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. Journal of Clinical Investigation, 111, 231 239.
9. DeSimone J. Heller P. Hall L. Wiers D.Z. (1982) 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proceeding of the National Academy of Sciences of the United States of America, 9, 4428 4433.
10. Dresler W.F.C. Stein R. (1869) Ueber den Hydroxyharnstoff. Justus Liebigs Annals of Chemical Pharmacology, 150, 242 252.
11. Fibach E. Burk L.P. Schechter A.N. Noguchi C.T. Rodgers G.P. (1993) Hydroxyurea increases fetal hemoglobin in cultured erythroids cells derived from normal individuals and patients with sickle cell anemia or thalassemia. Blood, 81, 1630 1635.
12. Gladwin M.T. Shelhamer J.H. Ognibene F.P. Pease-Fye M.E. Nichols J.S. Link B. Patel D.B. Jankowski M.A. Pannell L.K. Schechter A.N. Rodgers G.P. (2002) Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. British Journal of Haematology, 116, 436 444.
13. Ikuta T. Ausenda S. Cappellini M.D. (2001) Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proceeding of the National Academy of Sciences of the United States of America, 98, 1847 1852.
14. International Committee for Standardization in Haematology (1967) Recommendation for haemoglobinometry in human blood. British Journal of Haematology, 13, Supplement, Abstract 71 Asakura T. (2003) Combined use of nonmyelosuppressive nitrosourea analogues with hydroxyurea in the induction of F-cell production in a human erythroleukemic cell line. Experimental Hematology, 31, 592 600.
15. King S.B. (2004) Nitric oxide production from hydroxyurea. Free Radical Biology & Medicine, 37, 737 744.
16. Kobzik L. Reid M.B. Bredt D.S. Stamler J.S. (1994) Nitric oxide in skeletal muscle. Nature, 372, 546 548.
17. Morris C.R. Vichinsky E.P. van Warmerdam J. Machado L. Kepka-Lenhart D. Morris Jr., S.M. Kuypers F.A. (2003a) Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. Journal of Pediatric Hematology/Oncology, 25, 629 634.
18. Morris C.R. Morris Jr., S.M. Hagar W. Van Warmerdam J. Claster S. Kepka-Lenhart D. Machado L. Kuypers F.A. Vichinsky E.P. (2003b) Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? American Journal of Respiratory and Critical Care Medicine, 168, 63 69.
19. Nahavandi M. Tavakkoli F. Wyche M.Q. Perlin E. Winter W.P. Castro O. (2002) Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. British Journal of Haematology, 119, 855 857.
20. Orringer E.P. Abraham D.J. Parker J.C. (1994) Development of drug therapy. In: Sickle Cell Disease: Basic Principle and Clinical Practice (ed. by S.H. Embury R.P. Hebbel N. Mohandas M.H. Steinberg pp. 861 871. Raven, New York, NY.
21. Ou C.N. Rognerud C.L. (1993) Rapid analysis of hemoglobin variants by cation-exchange HPLC. Clinical Chemistry, 39, 820 824.
22. Riggs M.G. Whittaker R.G. Neumann J.R. Ingram VM. (1977) n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature, 268, 462 464.
23. Schnog J.J. Jager E.H. van der Dijs F.P. Duits A.J. Moshage H. Muskiet F.D. Muskiet F.A. (2004) Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Annals of Hematology, 83, 371 375.
24. Tormanen C.D. (1990) Comparison of the properties of purified mitochondrial and cytosolic rat kidney transamidinase. International Journal of Biochemistry, 122, 1243 1250.